Entecavir in the treatment of chronic hepatitis B virus infection
- Anna SF Lok, MD
Anna SF Lok, MD
- Professor of Medicine
- University of Michigan Medical School
Entecavir (Baraclude) is an orally administered cyclopentyl guanosine analogue that has been approved for treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevation in serum aminotransferases or histologically active disease. Approval was based upon the results of three phase 3 trials involving a total of 1633 patients ages 16 and older who had chronic HBV infection, persistently elevated serum ALT levels (≥1.3x the upper limit of normal), and chronic inflammation on liver biopsy. Entecavir has also been studied in patients who were refractory to lamivudine and in HBV/HIV coinfected patients.
This topic review will discuss the treatment of chronic hepatitis B with entecavir. A general approach to patients with hepatitis B (including other treatment options) is presented separately. (See "Hepatitis B virus: Overview of management" and "Combination therapy for chronic hepatitis B virus infection" and "Tenofovir for the treatment of adults with chronic HBV infection".)
THE EFFICACY OF ENTECAVIR IN DIFFERENT PATIENT POPULATIONS
HBeAg-positive chronic hepatitis — Treatment with entecavir achieves hepatitis B e antigen (HBeAg) seroconversion in about 20 percent of patients with HBeAg-positive hepatitis B virus (HBV) who have not previously been treated with nucleoside(tide) analogues [1-6]. In addition, one-year treatment is associated with a 5 to 7 log(10) reduction in mean HBV DNA levels and corresponding improvement in liver histology. The rate of virologic resistance is around 1 percent with up to five years of follow-up.
Versus lamivudine — A multinational trial included 715 patients with HBeAg-positive chronic HBV who were randomly assigned to entecavir (0.5 mg daily) or lamivudine (100 mg daily) for 48 weeks . Patients were eligible if they had HBV DNA levels ≥3 mEq/mL (approximately 600,000 international units/mL), a serum ALT ≥1.3 times the upper limit of normal, compensated liver disease, and had no or <12 weeks of nucleoside(t)e therapy for HBV previously.
At week 48, HBeAg seroconversion was observed in 21 percent of the entecavir group and 18 percent of the lamivudine group (table 1 and table 2). Serum HBV DNA decreased from baseline by an average of 6.86 log(10) compared with 5.39 log(10) in the lamivudine group. Suppression of HBV DNA to less than 0.7 mEq/mL (approximately 140,000 international units/mL) and normalization of serum ALT were observed significantly more often in the entecavir group (91 versus 65 percent and 78 versus 70 percent, respectively). Serum HBV DNA was undetectable by PCR assay in 67 percent of the entecavir group compared with 36 percent in the lamivudine group.To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106:1264.
- Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001.
- Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133:1437.
- Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:422.
- Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52:886.
- Ahn J, Lee HM, Lim JK, et al. Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther 2016; 43:134.
- Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009; 49:72.
- Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One 2014; 9:e98865.
- Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology 2016; 63:284.
- Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011.
- Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50:289.
- Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology 2011; 54:443.
- Ridruejo E, Adrover R, Cocozzella D, et al. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Pract 2011; 65:866.
- Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012; 19:377.
- Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49:1503.
- Lee JH, Cho Y, Lee DH, et al. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. Antimicrob Agents Chemother 2014; 58:1730.
- Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52:493.
- Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63:261.
- European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167.
- Jain MK, Zoellner CL. Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV. AIDS 2007; 21:2365.
- Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011; 54:236.
- Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011; 54:91.
- Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol 2013; 19:6665.
- Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53:62.
- Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52:176.
- Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58:1537.
- Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50:2001.
- Wu IC, Lai CL, Han SH, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010; 51:1185.
- Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol 2012; 57:508.
- Heo NY, Lim YS, Lee HC, et al. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53:449.
- Colonno RJ, Rose RE, Pokornowski K, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients (abstract). Hepatology 2006; 44 (Suppl 1):229A.
- Warner N, Locarnini SA, Edwards R, et al. Molecular modelling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy (abstract). Hepatology 2004; 40 (Suppl 1):245A.
- Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48:3498.
- Manns MP, Akarca US, Chang TT, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012; 11:361.
- Yang YJ, Shim JH, Kim KM, et al. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology 2014; 59:1303.
- Qiu YW, Huang LH, Yang WL, et al. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. Int J Infect Dis 2016; 43:43.
- Ridruejo E, Marciano S, Galdame O, et al. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. J Viral Hepat 2014; 21:590.
- Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013; 58:1888.
- THE EFFICACY OF ENTECAVIR IN DIFFERENT PATIENT POPULATIONS
- HBeAg-positive chronic hepatitis
- - Versus lamivudine
- - Versus adefovir
- - Versus tenofovir
- HBeAg-negative chronic hepatitis
- Patients previously treated with lamivudine
- Patients previously treated with adefovir
- HIV coinfected patients
- Severe exacerbation
- Decompensated cirrhosis
- Patients with minimally elevated ALT levels
- VIROLOGIC RESPONSE TO THERAPY
- OPTIMAL DURATION OF THERAPY
- RISK OF RELAPSE AFTER DISCONTINUING ENTECAVIR
- SUMMARY AND RECOMMENDATIONS